Finance

The Fundamental Facts on Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is an interesting stock at present. Now trading with a market value of 505.92M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For INO, the company currently has 22.9 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 153.31 million in total assets, balanced by 47.37 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Inovio Pharmaceuticals, Inc. (INO) saw -16.02 million in free cash flow last quarter, representing a quarterly net change in cash of 3.77 million. Perhaps most importantly where cash movements are concerned, the company saw about -15.23 million in net operating cash flow.



Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 10.38 million in total revenues. That represents a quarterly year/year change in revenues of 0.28 in sequential terms, the INO saw sales decline by 0.22.

But what about the bottom line? After all, that’s what really matters in the end. Inovio Pharmaceuticals, Inc. (INO) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 74.3 million, this means overall earnings per share of -0.31. Note, this compares with a consensus analyst forecast of -0.19 in earnings per share for its next fiscal quarterly report.




Is Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.36 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Inovio Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

Analyzing the Insider Data for Moleculin Biotech, ... Recent insider trends for Moleculin Biotech, Inc. (NASDAQ:MBRX) have caught the attention of investors. Analysts monitor insider data to understand th...
Are Lattice Semiconductor Corporation (LSCC)’... Recent insider trends for Lattice Semiconductor Corporation (NASDAQ:LSCC) have caught the attention of investors. Insider data is useful because it ca...
First Solar, Inc. (FSLR) Technical Analysis Indica... First Solar, Inc. (NASDAQ:FSLR) fell by -4.37% in Monday’s trading session from $48.06 to $45.96. The price has fallen in 6 of the last 10 days and is...
The Fundamental Case for and Against Keryx Biophar... Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is an interesting stock at present. Now trading with a market value of 765.79M, the company has a mix of ...
Critical Comparison: Duke Realty Corporation (DRE)... Duke Realty Corporation (NYSE:DRE) and CubeSmart (NYSE:CUBE) are the two most active stocks in the REIT - Industrial industry based on today’s trading...